TITLE:
Vaccines and Antibodies for Therapeutic Use in Cancers
AUTHORS:
G. P. Talwar, Jagdish C. Gupta, M. Diwan, J. Frick, S. K. Sharma, S. N. Wadhwa, R. M. Gupta, S. K. Gupta, Shilpi Purswani, Hemant K. Vyas
KEYWORDS:
Human Chorionic Gonadotropin (hCG), LHRH, Prostate Cancer, Breast Cancer, Antibody-Curcumin Magic Bullets
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.6,
June
14,
2016
ABSTRACT: This review describes briefly the beneficial use of two vaccines developed
by us for treatment of cancers. The vaccine against Luteinizing Hormone Releasing
Hormone (LHRH) is effective in carcinoma of prostate as well as in breast cancers
dependent on androgens and estrogens respectively. LHRH being identical in both
males and females, the same vaccine is usable in both Prostate and Breast steroid
hormones-dependent-cancers. Monoclonal antibodies are finding therapeutic utility
in several cancers, and many have received Drugs Regulatory approval. The monoclonals
developed by us against hCG and against epitopes present on androgen-independent
castration resistant prostate cancers are briefly recapitulated. Anti-hCG antibodies
kill several cancers expressing hCG. An example is given of A549 lung carcinoma.
MoAb730 and MoAb7B2G10 kill DU-145 and PC-3 androgen-independent castration resistant
prostate cancer cells. Some cancers such as MOLT-4, a T-lymphoblastic leukemia,
though expressing hCG are not killed by PiPP, the high affinity anti-hCG antibody.
Linking the antibody to curcumin however works like a “Magic Bullet”. All MOLT-4
cells are killed by this conjugate, the antibody homes selectively to cancer cells
expressing hCG to deliver curcumin which exercises the killing effect. A recombinant
vaccine, hCGβ-LTB (human chorionic gonadotropin
subunit β linked to B subunit of heat-labile
enterotoxin of E. coli) has been made,
which induces high titre bioeffective antibodies not only in BalbC, but also in
other genetic strains of mice. The vaccine employs autoclaved Mycobacterium indicus pranii (MiP) as adjuvant.
MiP invigorates both humoral and cell mediated immune responses against Human chorionic
gonadotropin (hCG). Besides being a potent adjuvant, MiP used alone heals anogenital
warts in humans and has the property of preventing and curing SP2/O Myelomas in
mice.